Particle Acceleration in Cosmic Sites - Astrophysics Issues in our Understanding of Cosmic Rays

Laboratory experiments to explore plasma conditions and stimulated particle acceleration can illuminate aspects of the cosmic particle acceleration process. Here we discuss the cosmic-ray candidate source object variety, and what has been learned about their particle-acceleration characteristics. We identify open issues as discussed among astrophysicists. -- The cosmic ray differential intensity spectrum is a rather smooth power-law spectrum, with two kinks at the "knee" (~10^15 eV) and at the "ankle" (~3 10^18 eV). It is unclear if these kinks are related to boundaries between different dominating sources, or rather related to characteristics of cosmic-ray propagation. We believe that Galactic sources dominate up to 10^17 eV or even above, and the extragalactic origin of cosmic rays at highest energies merges rather smoothly with Galactic contributions throughout the 10^15--10^18 eV range. Pulsars and supernova remnants are among the prime candidates for Galactic cosmic-ray production, while nuclei of active galaxies are considered best candidates to produce ultrahigh-energy cosmic rays of extragalactic origin. Acceleration processes are related to shocks from violent ejections of matter from energetic sources such as supernova explosions or matter accretion onto black holes. Details of such acceleration are difficult, as relativistic particles modify the structure of the shock, and simple approximations or perturbation calculations are unsatisfactory. This is where laboratory plasma experiments are expected to contribute, to enlighten the non-linear processes which occur under such conditions.Comment: accepted for publication in EPJD, topical issue on Fundamental physics and ultra-high laser fields. From review talk at "Extreme Light Infrastructure" workshop, Sep 2008. Version-2 May 2009: adjust some wordings and references at EPJD proofs stag

Using statistical and artificial neural networks to predict the permeability of loosely packed granular materials

Well-known analytical equations for predicting permeability are generally reported to overestimate this important property of porous media. In this work, more robust models developed from statistical (multivariable regression) and Artificial Neural Network (ANN) methods utilised additional particle characteristics [‘fines ratio’ (x50/x10) and particle shape] that are not found in traditional analytical equations. Using data from experiments and literature, model performance analyses with average absolute error (AAE) showed error of ~40% for the analytical models (Kozeny–Carman and Happel–Brenner). This error reduces to 9% with ANN model. This work establishes superiority of the new models, using experiments and mathematical techniques

Dust in Supernovae and Supernova Remnants I : Formation Scenarios

Supernovae are considered as prime sources of dust in space. Observations of local supernovae over the past couple of decades have detected the presence of dust in supernova ejecta. The reddening of the high redshift quasars also indicate the presence of large masses of dust in early galaxies. Considering the top heavy IMF in the early galaxies, supernovae are assumed to be the major contributor to these large amounts of dust. However, the composition and morphology of dust grains formed in a supernova ejecta is yet to be understood with clarity. Moreover, the dust masses inferred from observations in mid-infrared and submillimeter wavelength regimes differ by two orders of magnitude or more. Therefore, the mechanism responsible for the synthesis of molecules and dust in such environments plays a crucial role in studying the evolution of cosmic dust in galaxies. This review summarises our current knowledge of dust formation in supernova ejecta and tries to quantify the role of supernovae as dust producers in a galaxy.Peer reviewe

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Stability and stabilisation of the lattice Boltzmann method Magic steps and salvation operations

We revisit the classical stability versus accuracy dilemma for the lattice Boltzmann methods (LBM). Our goal is a stable method of second-order accuracy for fluid dynamics based on the lattice Bhatnager–Gross–Krook method (LBGK). The LBGK scheme can be recognised as a discrete dynamical system generated by free-flight and entropic involution. In this framework the stability and accuracy analysis are more natural. We find the necessary and sufficient conditions for second-order accurate fluid dynamics modelling. In particular, it is proven that in order to guarantee second-order accuracy the distribution should belong to a distinguished surface – the invariant film (up to second-order in the time step). This surface is the trajectory of the (quasi)equilibrium distribution surface under free-flight. The main instability mechanisms are identified. The simplest recipes for stabilisation add no artificial dissipation (up to second-order) and provide second-order accuracy of the method. Two other prescriptions add some artificial dissipation locally and prevent the system from loss of positivity and local blow-up. Demonstration of the proposed stable LBGK schemes are provided by the numerical simulation of a 1D shock tube and the unsteady 2D-flow around a square-cylinder up to Reynolds number O(10000)